202 related articles for article (PubMed ID: 16366590)
1. Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprotection.
Jacobson KA; Gao ZG; Tchilibon S; Duong HT; Joshi BV; Sonin D; Liang BT
J Med Chem; 2005 Dec; 48(26):8103-7. PubMed ID: 16366590
[TBL] [Abstract][Full Text] [Related]
2. Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury.
Gazoni LM; Walters DM; Unger EB; Linden J; Kron IL; Laubach VE
J Thorac Cardiovasc Surg; 2010 Aug; 140(2):440-6. PubMed ID: 20398911
[TBL] [Abstract][Full Text] [Related]
3. Adenosine A₂A and A₂B receptors are both required for adenosine A₁ receptor-mediated cardioprotection.
Zhan E; McIntosh VJ; Lasley RD
Am J Physiol Heart Circ Physiol; 2011 Sep; 301(3):H1183-9. PubMed ID: 21743001
[TBL] [Abstract][Full Text] [Related]
4. (N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.
Tchilibon S; Joshi BV; Kim SK; Duong HT; Gao ZG; Jacobson KA
J Med Chem; 2005 Mar; 48(6):1745-58. PubMed ID: 15771421
[TBL] [Abstract][Full Text] [Related]
5. Design and in Vivo Characterization of A
Tosh DK; Rao H; Bitant A; Salmaso V; Mannes P; Lieberman DI; Vaughan KL; Mattison JA; Rothwell AC; Auchampach JA; Ciancetta A; Liu N; Cui Z; Gao ZG; Reitman ML; Gavrilova O; Jacobson KA
J Med Chem; 2019 Feb; 62(3):1502-1522. PubMed ID: 30605331
[TBL] [Abstract][Full Text] [Related]
6. Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors.
Alnouri MW; Jepards S; Casari A; Schiedel AC; Hinz S; Müller CE
Purinergic Signal; 2015 Sep; 11(3):389-407. PubMed ID: 26126429
[TBL] [Abstract][Full Text] [Related]
7. Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.
Melman A; Gao ZG; Kumar D; Wan TC; Gizewski E; Auchampach JA; Jacobson KA
Bioorg Med Chem Lett; 2008 May; 18(9):2813-9. PubMed ID: 18424135
[TBL] [Abstract][Full Text] [Related]
8. Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions.
Tosh DK; Deflorian F; Phan K; Gao ZG; Wan TC; Gizewski E; Auchampach JA; Jacobson KA
J Med Chem; 2012 May; 55(10):4847-60. PubMed ID: 22559880
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological activity of N6-substituted-4'-thioadenosines at the human A3 adenosine receptor.
Jeong LS; Lee HW; Kim HO; Jung JY; Gao ZG; Duong HT; Rao S; Jacobson KA; Shin DH; Lee JA; Gunaga P; Lee SK; Jin DZ; Chun MW; Moon HR
Bioorg Med Chem; 2006 Jul; 14(14):4718-30. PubMed ID: 16603368
[TBL] [Abstract][Full Text] [Related]
10. The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel.
Wan TC; Ge ZD; Tampo A; Mio Y; Bienengraeber MW; Tracey WR; Gross GJ; Kwok WM; Auchampach JA
J Pharmacol Exp Ther; 2008 Jan; 324(1):234-43. PubMed ID: 17906066
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotection induced by adenosine A1 receptor agonists in a cardiac cell ischemia model involves cooperative activation of adenosine A2A and A2B receptors by endogenous adenosine.
Urmaliya VB; Church JE; Coupar IM; Rose'Meyer RB; Pouton CW; White PJ
J Cardiovasc Pharmacol; 2009 May; 53(5):424-33. PubMed ID: 19333129
[TBL] [Abstract][Full Text] [Related]
12. Nucleotide P2Y
Liston TE; Hinz S; Müller CE; Holstein DM; Wendling J; Melton RJ; Campbell M; Korinek WS; Suresh RR; Sethre-Hofstad DA; Gao ZG; Tosh DK; Jacobson KA; Lechleiter JD
Purinergic Signal; 2020 Dec; 16(4):543-559. PubMed ID: 33129204
[TBL] [Abstract][Full Text] [Related]
13. Cell-specific differential modulation of human trabecular meshwork cells by selective adenosine receptor agonists.
Karl MO; Peterson-Yantorno K; Civan MM
Exp Eye Res; 2007 Jan; 84(1):126-34. PubMed ID: 17070802
[TBL] [Abstract][Full Text] [Related]
14. 2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database searching.
Novellino E; Cosimelli B; Ehlardo M; Greco G; Iadanza M; Lavecchia A; Rimoli MG; Sala A; Da Settimo A; Primofiore G; Da Settimo F; Taliani S; La Motta C; Klotz KN; Tuscano D; Trincavelli ML; Martini C
J Med Chem; 2005 Dec; 48(26):8253-60. PubMed ID: 16366607
[TBL] [Abstract][Full Text] [Related]
15. Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury.
Tracey WR; Magee WP; Oleynek JJ; Hill RJ; Smith AH; Flynn DM; Knight DR
Am J Physiol Heart Circ Physiol; 2003 Dec; 285(6):H2780-7. PubMed ID: 12919933
[TBL] [Abstract][Full Text] [Related]
16. 5'-C-Ethyl-tetrazolyl-N(6)-substituted adenosine and 2-chloro-adenosine derivatives as highly potent dual acting A1 adenosine receptor agonists and A3 adenosine receptor antagonists.
Petrelli R; Torquati I; Kachler S; Luongo L; Maione S; Franchetti P; Grifantini M; Novellino E; Lavecchia A; Klotz KN; Cappellacci L
J Med Chem; 2015 Mar; 58(5):2560-6. PubMed ID: 25699637
[TBL] [Abstract][Full Text] [Related]
17. Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant?
McIntosh VJ; Lasley RD
J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):21-33. PubMed ID: 21335481
[TBL] [Abstract][Full Text] [Related]
18. Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.
Gao ZG; Kim SK; Biadatti T; Chen W; Lee K; Barak D; Kim SG; Johnson CR; Jacobson KA
J Med Chem; 2002 Sep; 45(20):4471-84. PubMed ID: 12238926
[TBL] [Abstract][Full Text] [Related]
19. Cooperative cardioprotection through adenosine A1 and A2A receptor agonism in ischemia-reperfused isolated mouse heart.
Urmaliya VB; Pouton CW; Ledent C; Short JL; White PJ
J Cardiovasc Pharmacol; 2010 Oct; 56(4):379-88. PubMed ID: 20930592
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-uronamides as highly potent and selective agonists at the human A3 adenosine receptor.
Jeong LS; Lee HW; Jacobson KA; Kim HO; Shin DH; Lee JA; Gao ZG; Lu C; Duong HT; Gunaga P; Lee SK; Jin DZ; Chun MW; Moon HR
J Med Chem; 2006 Jan; 49(1):273-81. PubMed ID: 16392812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
